Issue: February 2016
January 19, 2016
2 min read
Save

New advances in IOL technology increase patient satisfaction

Issue: February 2016
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

WAIKOLOA, Hawaii — The advancement in IOL technology has increased patient satisfaction, according to a speaker here.

“The new IOLs we have today are dramatically improved and have really improved patient satisfaction,” Eric D. Donnenfeld, MD, said at Hawaiian Eye. “And we have a lot of new technology on the horizon as well. It is a very exciting time to be involved in presbyopia correction.”

Eric D. Donnenfeld

There are a variety of multifocal options because no single style multifocal IOL can fill in all the gaps throughout the entire range of vision, he said.

“We started with ReSTOR and Tecnis +4.0 D in the U.S., and we have come up with some low adds. These are designed to meet the various near and intermediate tasks,” Donnenfeld said.

Patient satisfaction with multifocal IOLs is about their quality of distance vision, he said.

“If you can’t deliver quality distance vision to patients who have multifocal IOLs, they are going to be unhappy regardless of where the defocus curve is,” he said.

According to a study, 87% of patients implanted with the Tecnis low-add multifocal +4.0 D IOL, 94% of patients implanted with the Tecnis low-add multifocal +3.25 D IOL and 97% of patients implanted with the Tecnis low-add multifocal +2.75 D IOL said they would elect to have the same IOL implanted again, Donnenfeld said.

In another study where 138 patients were implanted with the AcrySof IQ RESTOR +3.0 D IOL and 131 patients were implanted with the AcrySof IQ RESTOR +4.0 D IOL, over 85% of patients said that they would have the same implant again, he said.

“For me, the most exciting new technology just coming are new extended depth of focus lens, which should be here about this time next year. We completed the FDA trial, and we have seen the results,” he said.

“I strongly advocate to reduce the visual disturbances and whatever reading you give them, patients will be happy. New lenses are exciting. We will have toric lenses, we will have high focus lenses, we will have extended depth of focus lenses coming... I think you will find the new lenses much more forgiving, and the results much better,” Donnenfeld said. by Nhu Te

Reference:

Donnenfeld E. What’s new in multifocal IOLs. Presented at: Hawaiian Eye 2016 meeting; Jan. 18, 2016; Waikoloa, Hawaii.

Disclosure: Donnenfeld reports he is a consultant for AcuFocus, Allergan, Alcon, Abbott Medical Optics, Aquesys, Bausch + Lomb, Beaver-Visitec, CRST, Elenza, Glaukos, Icon Biosciences, Kala Pharmaceuticals, Katerna, LacriPen, Mati Pharmaceuticals, Merck, Mimetogen, Novabay, Novaliq, OcuHub, Odyssey Medical, Omega Ophthalmics, Omeros, Pfizer Ophthalmics, PRN Pharmaceutical, RPS, Shire, Strathspey Crown, Tearlab, TearScience, The Laser Centers, TrueVision, Versant Venture, WaveTec and Carl Zeiss Meditec.